Abstract

23
The measurement of glomerular filtration rate by the clearance of 24 inulin or creatinine has evolved over the past fifty years into an estimated value 25 (eGFR) based solely on plasma creatinine concentration. We have examined some 26 of the misconceptions and misunderstanding of the classification of renal disease 27 and its course which have followed this evolution. Further, renal plasma flow and 28 tubular function, which in the past were estimated by the clearance of the 29 exogenous aryl amine, para amino hippurate, are no longer measured. in Health and Disease (47) and was based, largely on measurement of infused substances that were 63 transported by the renal tubule and could be measured in urine. The rate of glomerular filtration, 64 measured by the clearance of inulin, was described in a mere 7 pages by Smith (47) . 65
Measurement of glomerular filtration rate, renal blood flow and the relationship between 66 glomerular filtration and renal blood flow, termed the filtration fraction, formed the basis for our 67 current understanding of many nephrologic disorders. The observation that renal plasma flow was 68 reduced, at times markedly, out of proportion to glomerular filtration is the basis for our understanding 69 of essential hypertension as a disorder of renal vasoconstriction (16). Indicator dilution curves recorded 70 across the renal vascular bed gave evidence that renal vasoconstriction was generalized rather than 71 focal (36). Measurements of deep renal vein pressure ("wedged renal vein pressure") suggested a 72 mechanism for the exaggerated natriuresis seen in hypertensive subjects (35). Reduced glomerular 73 filtration with normal or near normal renal plasma flow (low filtration fraction) was recognized as the 74 mechanism responsible for avid sodium retention and edema in acute diffuse glomerulonephritis (15) . 75
The parallel reduction in glomerular filtration and renal plasma flow was seen as evidence of "whole 76 nephron loss" in chronic renal disease (3). 77
The measurements of inulin and para-amino hippurate (PAH) in plasma and urine, which 78 provided such valuable insights into renal pathophysiology, are precise, but not easily carried out in 79 routine chemistry laboratories. Further, these clearance measurements require infusion and 80 maintenance of steady plasma concentrations of inulin and PAH during a timed period of urine 81 collection, limiting application to clinical settings (45, 47) . A reasonable approximation of inulin 82 clearance (GFR) was introduced with measurement of the clearance of endogenous creatinine whose 83 excretion is largely via glomerular filtration. As a consequence, the clearance of creatinine (C cr ), which 84 can be measured in routine automated chemistry laboratories, came to serve as a substitute, albeit not 85 a perfect one, for estimation of glomerular filtration rate. However, this estimate also required 86 collection of a carefully timed urine collection, sometimes a source of considerable error. The evolution 87 which followed resembles a "slippery slope". Since creatinine is produced in muscles at a fairly constant 88 rate, it was reasoned that glomerular filtration rate could be estimated (eGFR) from measurement of 89 creatinine, corrected for body size and age, in a single blood sample (32). It was assumed that renal 90 tubular function (renal plasma flow and tubular secretion) declined in parallel with glomerular filtration 91 (3). A lack of attention to renal blood flow and tubular function over the years followed this unproven 92
assumption. 93
The ability to obtain a quantitative assessment of glomerular filtration rate from a readily 94 available blood test held the promise of retaining a focus on physiology in the care of patients with renal 95 disease. However, we submit that the characterization of renal function solely by estimation of eGFR, 96 whether by measurement of creatinine or, its surrogate, cystatin (8), has presented a number of 97 problems in our understanding of the underlying pathophysiology of clinical renal disease and its 98 management. 99
First, utilization of eGFR as the basis for the definition of the stages of chronic kidney disease, 100 CKD (31), can be misleading as it equates all instances of reduced glomerular filtration rate as evidence 101 of renal disease, ignoring the role of hemodynamics in determining the rate of glomerular filtration. 102
However, we know that GFR can fluctuate in a normal individual between a daytime high of 122 103 ml/min/1.73 m 2 to a nighttime low of 86 ml/min/1.73 m 2 (29). The KDIGO (Kidney Disease Improving 104
Global Outcomes) guidelines clearly state the "The presence of chronic kidney disease should be 105 established, based on presence of kidney damage and level of kidney function (glomerular filtration rate 106
[GFR]), irrespective of diagnosis" (31). This implies that stage 1 eGFR is the beginning of renal disease. 107
There is abundant evidence that many forms of progressive renal disease may be advanced before 108 serum creatinine is elevated or eGFR reduced. Further, this classification suggests that patients proceed 109 from Stage I to Stage 5 CKD with time. This has proven to be an erroneous assumption, only partially 110 corrected by the later inclusion of the presence or absence of proteinuria in the prognosis (6). As stated 111 by Couser (7) "Identification of stages of CKD implies, perhaps unintentionally, that CKD is a progressive 112 process with those afflicted moving eventually from earlier to more advanced stages of disease. 113
Although this clearly happens in many patients with defined forms of kidney disease like diabetes and 114 glomerulonephritis, (and we would add, polycystic kidney disease (14)) there is a paucity of data 115 documenting such progression in patients with CKD defined only as GFR < 60 ml/min or GFR < 60 ml/min 116 with microalbuminuria. Indeed, it is clear from several studies that many such patients do not progress 117 over several years of follow-up". There is abundant evidence that patients in CKD categories 2-4 are far 118 more likely to die of cardiovascular disease than uremia (27) . 119 Second, eGFR is used to define "acute kidney injury" (AKI) replacing the older more 120 physiologically-based differentiation between "pre-renal" or hemodynamically mediated reduction in 121 glomerular filtration, and intrinsic tubular injury. Further, identifying AKI by an increase in serum 122 creatinine or decline in eGFR, has led to the belief that this injury occurs days after the insult, 123 hemodynamic or toxic, since several days may pass before serum creatinine is significantly increased to 124 the point that calculated eGFR is significantly reduced (43, 54). There is good evidence that the 125 physiologic changes in acute kidney injury or "tubular necrosis" occur very early in many instances (40) . 126
The search for biomarkers of acute kidney injury, many of which are proteins derived from the renal 127 tubule, has not fully replaced an understanding of the hemodynamics. 128
Third, the short-cuts that allowed estimation of glomerular filtration from a routine blood test 129 were introduced to increase awareness of renal function impairment in the general evaluation of 130 patients by family physicians and surgeons so that they might institute measures to delay the progress 131 of renal disease or control early manifestations of renal failure. To that end, they have been successful. 132
However, recent studies (12) found that estimated glomerular filtration rate (eGFR) in patients with CKD 133 stages 2 to 5, not on dialysis, was barely and inconsistently associated with plasma concentrations of 134 protein-bound uremic toxins which are now believed to be the major determinants of outcome in CKD. 135
These data strongly suggest that factors other than GFR are more powerful determinants of uremic 136 symptoms and outcome. These include renal tubular secretion of protein-bound uremic retention 137 solutes (26, 33, 37, 52) , diet content of toxin precursors, toxin production by gut bacteria, and gut transit 138 time (1, 13, 39, 53, 55) . Further, impaired proximal tubular secretion is now thought to contribute to the 139 increased plasma levels of trimethylamine oxide, TMAO (23, 48, 50) and tissue calcification (25) compete for transport is very long (5, 9). It seems reasonable that competition between excreted 157 solutes should be considered in prescribing drugs just as consideration is given to propensity for 158 hemorrhage or thrombosis, G -6-PD deficiency, or Cytochrome P-450 status (9). Finally, adjusting drug 159 dosage on the basis of eGFR may result in serious over dosage in the case of drugs whose excretion is 160 largely via secretion. 161
The conclusion of this critique is that measurement of serum creatinine and reporting of eGFR, 162 though apparently simplifying diagnosis and classification, is undermined by potentially serious errors 163 and cannot replace quantitative and qualitative measurements of renal tubular function. 164
In a recent review, Suchy-Dicey et al (49) wrote, "Proximal tubule secretion represents an 165 essential kidney function for rapidly clearing endogenous substances and administered medications 166 from the circulation, including protein-bound molecules. Moreover, tubular secretion represents the 167 primary renal mechanism responsible for the elimination of most administered drugs and their 168 metabolites. Despite the biologic importance of proximal tubule secretion, this function is infrequently 169 measured because of uncertainty regarding specific endogenous compounds that are cleared by 170 secretion, lack of validated laboratory assays for secreted metabolites, and the cumbersome nature of 171 timed urine collection". There is increasing evidence that the most life-threatening consequences of7 advanced renal disease, particularly uremic cardiomyopathy characterized by heart failure, arrhythmias 173 and sudden death (22), are more likely related to the accumulation of uremic solutes that are protein-174 bound and therefore not filtered or readily dialyzable, but rather, are actively secreted by transporters 175 in the proximal renal tubule (44). Organic anion transporters (OATs) in the kidney serve to facilitate the 176 secretion of protein-bound solutes, such as indoxyl sulfate and p-cresyl sulfate, considered to be 177 important gut-derived uremic toxins (2, 13). 178
Grantham reported (18-21) that isolated rabbit proximal renal tubules were able to secrete 179 fluid, i.e., to produce "urine", and that the rate of fluid secretion was increased when p-amino hippurate 180 was added to the bathing medium. It seems likely that the driving force for osmotic secretion of water is 181 the solute concentration attained in the proximal tubule segment. These studies revealed the enormous 182 transport work proximal tubules can channel to raise urine PAH levels as high as 39 millimoles per liter 183 will be necessary to establish that the removal of hippurate is virtually complete on a single pass 249 through the kidney. This could be tested easily by comparing peripheral venous and simultaneous renal 250 venous hippurate concentrations. Further, hippuric acid, unlike creatinine, is not produced at a constant 251 rate. Hippuric acid is generated by the acylation of glycine with benzoyl chloride, in large part influenced 252 by the gut microbiome (30). The plasma concentration of hippurate is determined by the rate of 253 production, which, like other microbiome-generated substances, may be assumed to be dependent on 254 several factors, viz, dietary substrates, the gut microbiome, and gut transit time as well as its secretion. 255
While a timed urine collection will be required to measure the clearance of hippurate, it seems likely 256 that plasma hippurate concentration during the period of urine sampling will not vary measurably. Porter Lecture on the Kidney (46) wrote of prochordates dating 500 million years ago. "These early 272 marine ancestors were in osmotic equilibrium with the sea and evolved a kidney that consisted solely of 273 tubules that served to secrete nitrogenous wastes into a coelome that connected with the exterior. 274
When life moved into fresh water, glomerular filtration evolved as the mechanism by which fish 275 maintained osmotic integrity and the tubules acquired transporters which reclaimed the filtered glucose 276 and other "valuable substances," but these fish still relied on tubular secretion to dispose of toxic 277
wastes" (italics ours). 278
The importance of renal tubular function in determining the outcome of chronic renal disease is 279 suggested by the finding that patients with end-stage renal disease with "residual renal function, RRF", 280 usually defined as producing 100 ml of urine daily while receiving hemodialysis or peritoneal dialysis, 281
have a better quality of life and longer survival than patients who are anuric (2, 51). This difference in 282 outcome, estimated to be equivalent to prolonging hemodialysis treatment by approximately 30 283 minutes, is not likely related to the glomerular filtration contributed by RRF (51). Prolonged 284 hemodialysis did not result in comparable improvement in outcome in the Hemo study (11). It seems 285 reasonable to postulate that RRF in patients receiving hemodialysis or peritoneal dialysis reflects the 286 contribution of proximal tubular solute excretion and more efficient removal of protein-bound uremic 287 solutes. The best studied of these uremic retention solutes, indoxyl sulfate, one of a very few poorly 288 dialyzable uremic retention solutes identified in a metabolomic screen (42), appears to exert its adverse 289 cardiovascular effect by binding to the cytoplasmic aryl hydrocarbon receptor (AHR) which acts as a 290 nuclear transcription factor mediating macrophage migration, oxidative stress and TGF beta signaling 291 (17) . 292
The management of renal failure, which, since the development of hemodialysis and peritoneal 293 dialysis, has been guided by estimates of glomerular filtration rate and the tacit assumption that dialysis 294 provides an efficient means of removing offensive solutes, will see important changes in strategy when 295 the generation and secretion of protein-bound uremic solute are better defined. Current practices 296 regarding the indications for and the time of institution of dialysis as well as the frequency of dialysis 297 treatments may be revised when these decisions are based on knowledge of the concentration of 298 uremic retention solutes (toxins) as well as hippurate. Renewed interest in and studies of the tubular 299 transport and clearance of hippurate (i.e., renal plasma flow) and related toxic aryl acids could help 300 move nephrology away from the glomerulocentic perspective that has stymied progress toward early 301 treatment of progressive renal disorders 302
